Aldeyra Therapeutics, Inc. (ALDX) financial statements (2020 and earlier)

Company profile

Business Address 131 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:76474325289
Cash and cash equivalents52472012159
Short-term investments25 231313 
Other undisclosed cash, cash equivalents, and short-term investments   (0)0 
Other undisclosed current assets1471000
Total current assets:77954425289
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment000000
Other undisclosed noncurrent assets 00 00
Total noncurrent assets:000000
TOTAL ASSETS:77954425289
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1283222
Accounts payable131010
Accrued liabilities1152211
Employee-related liabilities     0
Taxes payable     0
Interest and dividends payable     0
Debt0 0000
Other undisclosed current liabilities     (1)
Total current liabilities:1283221
Noncurrent Liabilities
Long-term debt and lease obligation14 1111
Long-term debt, excluding current maturities14 1111
Operating lease, liability0
Total noncurrent liabilities:14 1111
Total liabilities:2785433
Stockholders' equity
Stockholders' equity attributable to parent, including:51874022256
Common stock00000 
Additional paid in capital237225139998353
Accumulated other comprehensive income (loss)0(0)(0)0(0) 
Accumulated deficit(186)(139)(100)(77)(59)(47)
Other undisclosed stockholders' equity attributable to parent     0
Total stockholders' equity:51874022256
TOTAL LIABILITIES AND EQUITY:77954425289

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(55)(40)(22)(19)(12)(7)
Other undisclosed operating loss(7)     
Operating loss:(61)(40)(22)(19)(12)(7)
Nonoperating income (expense)210(0)(0)2
Investment income, nonoperating210000
Interest and debt expense(0)(0)(0)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(60)(39)(22)(19)(12)(5)
Other undisclosed income from continuing operations before income taxes0     
Loss from continuing operations before income taxes:(60)(39)(22)(19)(12)(5)
Income tax benefit1     
Net loss:(58)(39)(22)(19)(12)(5)
Other undisclosed net income attributable to parent000000
Net loss attributable to parent:(58)(39)(22)(19)(12)(5)
Preferred stock dividends and other adjustments     34
Other undisclosed net loss available to common stockholders, basic     (39)
Net loss available to common stockholders, basic:(58)(39)(22)(19)(12)(10)
Other undisclosed net loss available to common stockholders, diluted     (2)
Net loss available to common stockholders, diluted:(58)(39)(22)(19)(12)(12)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(58)(39)(22)(19)(12)(5)
Other comprehensive income (loss)00(0)0(0) 
Comprehensive loss:(58)(39)(22)(19)(12)(5)
Other undisclosed comprehensive income, net of tax, attributable to parent00000 
Comprehensive loss, net of tax, attributable to parent:(58)(39)(22)(19)(12)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: